H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Vivani Medical (VANI) to $3.50 from $4 and keeps a Buy rating on the shares after the company recently reported its 2025 results, citing an increased share count for the firm’s lowered target. The firm believes NPM-139 is uniquely positioned to potentially offer efficacy comparable to Wegovy while requiring only once or twice yearly administration, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VANI:
Disclaimer & DisclosureReport an Issue
